|
Duvelisib Clinical Trials
5 actively recruiting trials across 4 locations
▲ +1 trial since June 2026
Also known as: 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one, Copiktra, INK-1197, IPI 145, IPI-145 +1 more
Pipeline
Phase 1: 2Phase 2: 1Phase 3: 1Phase 1/2: 1
Top Sponsors
- Memorial Sloan Kettering Cancer Center2
- SecuraBio1
- Jonsson Comprehensive Cancer Center1
- City of Hope Medical Center1
Indications
- Cancer5
- T-cell Prolymphocytic Leukemia2
- Follicular Helper T-Cell Lymphoma1
- NK-Cell Lymphomas1
- T-cell Lymphomas1
Other1 trial
Duarte, California1 trial
Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
City of Hope Medical Center
Phase 2
Los Angeles, California1 trial
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
David Geffen School of Medicine at the University of California at Los Angeles
Phase 1/2
Miami, Florida1 trial
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
University of Miami (Data Collection Only)
Phase 1
Basking Ridge, New Jersey1 trial
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Memorial Sloan Kettering Basking Ridge (LimitedProtocol Activities)
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.